Laidlaw started coverage on shares of Strongbridge Biopharma (NASDAQ:SBBP) in a research note published on Tuesday, MarketBeat.com reports. The firm issued a buy rating and a $11.00 price objective on the biotechnology company’s stock.
Other equities research analysts have also issued reports about the stock. ValuEngine raised shares of Strongbridge Biopharma from a hold rating to a buy rating in a report on Thursday, November 1st. Cantor Fitzgerald set a $17.00 target price on shares of Strongbridge Biopharma and gave the stock a buy rating in a report on Wednesday, October 31st. Zacks Investment Research lowered shares of Strongbridge Biopharma from a hold rating to a sell rating in a report on Wednesday, November 7th. Finally, BidaskClub lowered shares of Strongbridge Biopharma from a sell rating to a strong sell rating in a report on Wednesday, September 5th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the stock. The stock presently has a consensus rating of Hold and an average target price of $14.13.
SBBP stock opened at $4.21 on Tuesday. Strongbridge Biopharma has a 1 year low of $3.85 and a 1 year high of $9.25. The company has a quick ratio of 3.11, a current ratio of 3.38 and a debt-to-equity ratio of 8.76. The company has a market cap of $199.45 million, a P/E ratio of -2.90 and a beta of -0.44.
A number of institutional investors and hedge funds have recently bought and sold shares of SBBP. Laurion Capital Management LP bought a new stake in Strongbridge Biopharma during the 2nd quarter worth approximately $101,000. Dynamic Technology Lab Private Ltd bought a new stake in shares of Strongbridge Biopharma in the 2nd quarter valued at $110,000. Cubist Systematic Strategies LLC bought a new stake in shares of Strongbridge Biopharma in the 2nd quarter valued at $130,000. Jane Street Group LLC bought a new stake in shares of Strongbridge Biopharma in the 2nd quarter valued at $154,000. Finally, Citadel Advisors LLC bought a new stake in shares of Strongbridge Biopharma in the 3rd quarter valued at $157,000. 65.68% of the stock is currently owned by hedge funds and other institutional investors.
About Strongbridge Biopharma
Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs. The company's commercial products include Keveyis, an oral carbonic anhydrase inhibitor for treating hyperkalemic, hypokalemic, and related variants of primary periodic paralysis in the United States; and Macrilen, an oral growth hormone secretagogue receptor agonist for use in the diagnosis of patients with adult growth hormone deficiency in the United States and Canada.
Featured Article: Compound Interest
Receive News & Ratings for Strongbridge Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strongbridge Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.